Search Database ICD-O-3 Code Lists

Name

Follicular lymphoma, grade 1

ICD-O-1 Morphology

9695/3: Follicular lymphoma, grade 1
9696/3: Malignant lymphoma, lymphocytic, poorly differentiated, nodular
Effective 1978 - 1991

ICD-O-2 Morphology

9695/3: Follicular lymphoma, grade 1
Effective 1992 - 2000

ICD-O-3 Morphology

9695/3: Follicular lymphoma, grade 1
Effective 2001 and later

Reportable

for cases diagnosed 1978 and later

Primary Site(s)

See Module 7
Most common sites of involvement: lymph nodes, spleen, bone marrow (BM), peripheral blood (PB), and Waldeyer ring, skin, duodenum, ocular adnex, breast and testis

Coding Manual: Hematopoietic Coding Manual (PDF)

Abstractor Notes

Follicular lymphoma, NOS (9690/3) histology is a generic disease description. DCO cases or path report only cases usually stay in this classification. The NOS histology may be the working diagnosis. Further review of the medical record should be done to look for the tests listed as definitive diagnosis.

The more specific follicular lymphomas are:
1. Follicular lymphoma, grade 1 (9695/3)
2. Follicular lymphoma, grade 2 (9691/3)
3. Follicular lymphoma, grade 3 [3A, 3B] (9698/3)

When a more specific diagnosis is identified, the histology should be changed to the more specific neoplasm name and code.

FL is graded according to the proportion of large cells (centroblasts). Studies suggest this histologic grading predicts clinical outcome, with more large cells behaving more aggressively and having a higher likelihood of transformation to diffuse large cell lymphoma.

1) Grade 1-2 (low grade): 0-15 centroblasts per HPF (9691/3)
2) Grade 1: 0-5 centroblasts per HPF (9695/3)
3) Grade 2: 6-15 centroblasts per HPF (9691/3)
4) Grade 3: > 15 centroblasts per HPF (9698/3)
5) Grade 3A: Centrocytes present (9698/3)
6) Grade 3B: Solid sheets of centroblasts (9698/3)

Most patients present with widespread disease, including peripheral and central (abdominal and thoracic) lymphadenopathy and splenomegaly. The BM is involved in 40-70%.

Only 1/3 of patients present with stage I or II at the time of diagnosis.

When any area of diffuse large-B-cell lymphoma (DLBCL) is present in a FL the disease should be reported as diffuse large B-cell lymphoma (9680/3) (See PH rules).

Diagnostic Confirmation

This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.

Grade

See Abstractor Notes

Module Rule

None

Alternate Names

Diffuse, follicular lymphoma, grade 1
Follicular lymphoma, duodenal type (C170)
Follicular lymphoma, diffuse, grade 1
Follicular lymphoma, small cleaved cell
Grade 1, follicular lymphoma, diffuse
Malignant lymphoma, lymphocytic, poorly differentiated, nodular [OBS]
Malignant lymphoma, small cleaved cell, follicular [OBS]
Primary intestinal follicular lymphoma

Definition

Follicular lymphoma (FL) is a neoplasm composed of follicle centre (germinal center) B cells (typically both centrocytes and centroblasts/large transformed cells), which usually has at least a partially follicular pattern. Progression in cytological grade is common during the natural history of the disease.

There are several variants/subtypes of Follicular lymphoma

1) Diffuse variant of follicular lymphoma. See 9690/3.
2) Duodenal-type follicular lymphoma. See below.
3) Large B-cell lymphoma with IRF4 rearrangement. See 9698/3.
4) Pediatric-type follicular lymphoma. See 9690/3.
5) Testicular follicular lymphoma. See 9698/3.

Duodenal-type follicular lymphoma in the gastrointestinal tract occur in the small intestine, usually with involvement of the duodenum. Duodenal-type FL is a specific variant of FL defined by distinctive clinical and biological features. The lesions are predominantly found in the second portion of the duodenum, presenting as multiple small polyps, often as an incidental finding on endoscopy performed for other reasons. Most patients have localized disease.

Definitive Diagnostic Methods

FISH
Genetic testing
Histologic confirmation
Immunophenotyping

Genetics Data

CREBBP mutation
KMT2D (also called MLL2) mutation
MEF2B mutation
MYC gain
TNFAIP3 (also called A20) deletion, mutation
TNFRSF14 deletion, mutation

Immunophenotyping

BCL2+ (expression/positive)
BCL6+ (expression/positive)
CD5- (no expression/negative)
CD10+ (expression/positive)
CD19+ (expression/positive)
CD20+ (expression/positive)
CD22+ (expression/positive)
CD23+ (expression/positive)
CD43- (no expression/negative)
CD79a+ (expression/positive)
GCET1+ (expression/positive)
GCET2 (HGAL)+ (expression/positive)
IgD- (no expression/negative)
IgM+ (expression/positive)
LMO2+ (expression/positive)
PAX5+ (expression/positive)

Treatments

Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Immunotherapy
Radiation therapy

Transformations to

Transformations from

None

Same Primaries

Corresponding ICD-9 Codes

202.0 Nodular lymphoma

Corresponding ICD-10 Codes

C82.0 Non-Hodgkin lymphoma small cleaved cell, follicular

Corresponding ICD-10-CM Codes (U.S. only)

C82.0 Follicular lymphoma grade I (effective October 01, 2015)

Signs and Symptoms

Drenching night sweats
Fatigue
Fever (for no known reason)
Lymphadenopathy (abdominal and thoracic)
Painless swelling in the lymph nodes in the neck, underarm, groin, or stomach
Skin rash or itchy skin
Splenomegaly
Weight loss (for no known reason)

Diagnostic Exams

Blood chemistry studies
Cytogenetics analysis
CT (CAT) scan
Flow cytometry
Immunohistochemistry
Immunophenotyping
Laparoscopy (rarely performed)
Laparotomy (rarely performed)
Lymph node biopsy
PET (positron emission tomography) scan

Progression and Transformation

25-35% of patients transform to DLBCL

Epidemiology and Mortality

Age: 60 years median age (rare occurrence under 20 years of age)
Incidence: Follicular lymphomas account for 20% of all lymhpomas
Sex: slight female predominance
Survival: 8-15 years median survival, closely related to the extent of the disease at diagnosis

Sources

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 266-281

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577

National Cancer Institute
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
Glossary